Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the following presentations will be presented at the 64 th ASH (American Society Hematology) Annual Meeting taking place from December 10-13, 2022, in New Orleans, Louisiana
By AP News
Published - Nov 04, 2022, 02:07 AM ET
Last Updated - Jun 17, 2024, 04:51 AM EDT
MARSEILLE, France--(BUSINESS WIRE)--Nov 4, 2022--
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the following presentations will be presented at the 64 th ASH (American Society Hematology) Annual Meeting taking place from December 10-13, 2022, in New Orleans, Louisiana.
